North Dakota Retirement and Investment Office Successfully Goes Live with Sagitec's Modernized Pension Administration System
The successful go-live of Neospin™ delivers a modern pension administration system with enhanced capabilities for North Dakota's Teachers' Fund for Retirement
ST. PAUL, Minn., March 11, 2025 (GLOBE NEWSWIRE) -- The North Dakota Retirement and Investment Office (RIO) in partnership with Sagitec, a leader in pension administration software solutions, successfully launched a modernized Pension Administration System (PAS) for the state's Teachers' Fund for Retirement (TFFR). This marks a significant milestone in a pension modernization project, which sought to enhance platform efficiency, security, and service for TFFR's more than 25,000 active, inactive, and retired members.
TFFR's legacy solution was first deployed in 2005 as a client-server application. RIO pursued a PAS modernization project to better support and maintain key activities, such as payroll reporting, contributions accounting, benefits calculations, tax processing, reporting, and integration capabilities. Neospin™, Sagitec's pension administration platform, provides TFFR with a full implementation of a modern, scalable solution that automates processes, improves data accuracy, and enhances the member and employer experience.
'The successful launch of our new pension administration system is a significant milestone for North Dakota's Teachers' Fund for Retirement, reinforcing our commitment to delivering exceptional service to our members and business partners,' said Chad Roberts, RIO's Deputy Executive Director / Chief Retirement Officer. 'With Neospin, our retirement services division can now provide faster, more secure, and more personalized service while improving efficiency across our operations.'
This new PAS features upgraded member and employer self-service portals, enhancing security and streamlining workflows for administrators and members. Neospin improves efficiency by automating processes and ensuring compliance through robust internal controls. It eliminates the need for custom application maintenance, reducing long-term costs and mitigating risks by ensuring data accuracy, security, and compliance with regulatory standards.
'The successful go-live marks an important step in the modernizing pension administration project,' said Subodh Murthi, Pension Managing Director at Sagitec. 'This implementation delivers enhanced efficiency, security, and member engagement, ensuring that the Teachers' Fund for Retirement can seamlessly serve North Dakota's educators now and in the future. We are proud to partner with the North Dakota Retirement and Investment Office to deliver a scalable, future-ready solution.'
With the successful go-live of Neospin in February 2025, TFFR transitioned to a modern pension administration system hosted on Microsoft Azure Cloud. This solution ensures that RIO can continue to meet the needs of TFFR's members effectively today and tomorrow.
About Sagitec Solutions
Sagitec is a leading software platform and solutions provider specializing in serving customers focused on solving complex, business-rule-driven problems. Sagitec provides evolutionary enterprise-grade solutions powered by their core platform, for pension administration, labor and employment, managed healthcare, and other industry organizations that want to accelerate excellence. With deep industry and domain experience in software implementation and systems integration, Sagitec is a partner that clients have trusted for over 20 years to drive their vision into action and value. Visit www.sagitec.com for more information.
Media Inquiries:mediainquiry@sagitec.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Propedix Inc. Announces Appointment of William Haegele to Board of Directors
BOSTON, June 4, 2025 /PRNewswire/ -- Propedix, a leading organization in Anti-infective topical Dermatology treatments, is pleased to announce a significant addition to its Board of Directors. Bill Haegele has been appointed to the Board of Directors as its first Independent Director and will play a pivotal role in driving the company's strategic initiatives and fostering continued growth. Propedix's first product, Dryello™ is a soon to be launched over-the-counter treatment for Athlete's Foot (tinea pedis), intended to both treat and prevent the fungal infection and its symptoms. With a proven track record of success in life sciences, public accounting, board governance, and general management, Mr. Haegele brings a wealth of experience and expertise to Propedix. A retired KPMG Partner, he offers deep knowledge in corporate governance and risk management. Bill has held leadership and board roles at several life sciences companies and is widely recognized for his innovative thinking, strategic leadership, and comprehensive understanding of the industry landscape. "We are thrilled to welcome Bill to the Board of Directors," said Niv Caviar, CEO of Propedix. "His visionary approach, strategic mindset, and passion for life science innovation align perfectly with our company's values and objectives. We are confident that his leadership will help propel us to new heights and reinforce our position as an industry leader." In this role, Bill will provide governance oversight over the company's financial, accounting, and corporate functions. His strategic vision and ability to help grow the company will be instrumental in guiding Propedix towards continued success and expansion as the Company develops and launches innovative dermatological topical anti-infective technologies. Mr. Haegele expressed enthusiasm about joining Propedix: "I am honored to join the Propedix team and look forward to contributing to the company's growth and success. I am confident that the Company's management team's decades of experience in developing and commercializing dermatological and anti-infective technologies will establish Propedix as a leader in innovative biopharma delivery and formulation solutions." About Propedix Propedix is a leading biopharma and consumer health company dedicated to advancing innovative treatments in topical dermatology and anti-infectives. Through a commitment to innovation, Propedix strives to provide effective, clinically tested solutions to fungal conditions. The Propedix team works diligently to expand the world of antifungal and anti-pathogen treatment through the use of their propriety delivery and formulation technology. Propedix has established itself as a trusted name in the industry, centering around improving the quality of life for each patient. About Dryello™ Dryello™ is a novel treatment for Athlete's foot that has been clinically tested to demonstrate strong effectiveness in mycological (fungal) cure and the reduction of symptoms associated with such infections including itch, perspiration, maceration, and scaling. Dryello's unique technology formulation and the supporting clinical data will be made available to the public upon commercial launch by early summer. View original content to download multimedia: SOURCE Propedix Inc.
Yahoo
an hour ago
- Yahoo
As Interest Grows for New Agents to Treat Thalassemia, Hematologists Begin Early Identification of Ideal Patients for Gene Therapies Vs. New Therapeutic Options
Spherix Global Insights' new patient audit on transfusion-dependent thalassemia reveals strong physician interest in emerging treatments like mitapivat and etavopivat, and provides insight into ideal candidates for curative gene therapies. EXTON, PA, June 04, 2025 (GLOBE NEWSWIRE) -- Despite the promise of new curative strategies for beta thalassemia, such as Casgevy (Vertex) and Zynteglo (bluebird bio), most transfusion-dependent thalassemia patients remain tethered to long-term transfusion support. Transfusions, while providing symptom relief, in turn create logistical barriers and their own clinical challenges. New data from Spherix Global Insights' independent chart audit, Patient Chart Dynamix™: Transfusion Dependent Thalassemia 2025 (US), is based on insight from 81 real-world patient charts submitted by 49 US-based hematologists. These data paint a complex picture of therapeutic inertia, growing anticipation for emerging treatments, and deep-seated frustration with limitations of current treatment options. Most transfusion-dependent beta thalassemia patients follow some regular transfusion schedule. That said, many receive them at relatively extended intervals: often once a month or even less frequently, though a small subset still require more frequent transfusions. This variation in treatment patterns, along with persistent symptoms and unmet needs highlighted in the chart audit, points to a strong opportunity for new therapies to improve care for a broad range of patients. Among surveyed hematologists, mitapivat (Agios) currently holds a slight edge in name recognition over etavopivat (Novo Nordisk). Interestingly, despite this difference in familiarity, physicians identified slightly more patients as potential candidates for etavopivat, hinting at a broader perceived clinical fit once awareness and understanding of the agent catch up. Chart audit data allows users to probe further into specific patient types which physicians perceive as better fits for either agent, as well as those who they do not perceive as candidates. This growing interest in emerging oral therapies reflects a broader desire among hematologists for more accessible, lower-burden treatment options. While most patients are theoretically eligible for curative approaches like gene therapy, the market still favors lower-barrier alternatives. These alternatives include oral therapies that do not require referral to specialized centers or extensive pre-conditioning, and brands with which they are more familiar given other indications such as Reblozyl (Bristol Myers Squibb). Disease-modifying therapies that are easier to prescribe and integrate into routine practice have the promise to significantly improve the lives of patients who would not qualify or want gene therapy. Access barriers compound the issue, with over half of physicians voicing frustration over payer restrictions that make it difficult to initiate optimal care. These challenges highlight a critical need – not just for clinical innovation, but also for strong manufacturer support in navigating reimbursement and expanding access. As the beta thalassemia landscape continues to evolve, hematologists are increasingly looking toward emerging therapies that are easier to prescribe, carry fewer logistical burdens than gene therapy, and offer clear reductions in transfusion dependency. Products like mitapivat and etavopivat are well-positioned to address this gap, assuming familiarity, confidence, and access grow in tandem – but the goal to cure patients of hemoglobinopathies still carries heavy weight, with desire to treat with gene therapy consistently growing. Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits. Insights reveal the 'why' behind treatment decisions, include year over year trending to quantify key aspects of market evolution, and integrate specialists' attitudinal & demographic data to highlight differences between stated and actual treatment patterns. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. CONTACT: Sarah Hendry, Hematology Franchise Head Spherix Global Insights 4848794284 in to access your portfolio
Yahoo
an hour ago
- Yahoo
Digitate Advances Agentic AI Platform to Accelerate Enterprises Towards Autonomous, Ticketless IT and Business Operations
New release launches purpose-built AI agents for IT and SREs as well as AI Assistants for CIOs to tackle complex enterprise tasks SANTA CLARA, Calif., June 04, 2025--(BUSINESS WIRE)--Digitate, a leading global SaaS provider of AIOps solutions, today announced the launch of its latest release designed to help IT and business leaders materialize their vision of autonomous enterprise and ticketless operations. Built on ignio™ – a powerful Agentic AI platform for IT and business operations, the new release introduces a suite of AI agents capable of handling even the most complex IT and business tasks with speed and precision, supercharging employee productivity and elevating business resiliency to new heights. "The complexity of today's enterprises needs intelligent agents that can understand, decide, and act with autonomy," said Rahul Kelkar, Chief Product Officer of Digitate. "With ignio, we envisioned a future of autonomous enterprises and pioneered the fusion of AI and automation from our very first release 10 years ago. Each subsequent release has empowered our customers to move away from reactive IT and step confidently into a world of proactive, self-driving ticketless operations. Our new Agentic AI platform and AI agents mark the next phase in this evolution, empowering CIOs, SRE teams, IT, and business operations to harness the power of ignio's agentic platform and AI agents to accelerate their autonomous enterprise journey." Digitate's Agentic AI framework reimagines enterprise AI as a system of autonomous, goal-oriented, and context-aware agents. These agents operate independently or collaboratively, continuously learning from their environment, understanding intent, and making informed decisions – elevating enterprise IT from rule-based automation to intelligent autonomy. Digitate's initial AI agents will address the following specific IT functions and personas: AI Agent for IT Event Management: Designed to autonomously ingest, correlate, and prioritize millions of IT events in real time, this agent cuts through noise, identifies patterns, and flags actionable insights—transforming event chaos into clear operational intelligence. AI Agent for Incident Resolution: Built to intelligently resolve incidents across hybrid environments, this agent combines contextual understanding with autonomous execution. It handles known issues and adapts to emerging ones—significantly reducing mean time to resolution (MTTR). AI Agent for SRE: Tailored for Site Reliability Engineering (SRE) teams, this agent enhances observability and tracking across the enterprise tech stack, enabling hands-on support and proactive reliability management. AI Assist for CIO: Engineered for CIOs who require unified, high-level data from across the enterprise to make informed decisions about strategy, governance, business continuity, and cost optimization. Starting today, Digitate will offer early previews of the new AI agents, with general availability to follow in the coming weeks. The AI agent for IT event management is now available for a free trial on Azure Monitor via Microsoft Azure Marketplace. To learn more about Digitate's new Agentic AI platform and AI agents, visit About Digitate Digitate builds AI technologies to power the autonomous enterprise. Our agentic AI platform – ignio™ – combines unified observability, AI-powered insights, and closed-loop automation to help enterprises across industries operate smarter, faster, and with greater resilience. Built on an agentic AI architecture, ignio enables proactive and predictive IT and business operations. Trusted by leading global enterprises and innovators, ignio accelerates innovation and maximizes business outcomes. Learn more at and follow Digitate on X and LinkedIn. View source version on Contacts Mark Button10Fold for DigitateTel: 408-310-2168digitate@ Sign in to access your portfolio
